272 related articles for article (PubMed ID: 21841326)
1. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
Kashihara K; Shinya T; Higaki F
Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
[TBL] [Abstract][Full Text] [Related]
2. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
[TBL] [Abstract][Full Text] [Related]
3. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
Kashihara K; Shinya T; Higaki F
J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
[TBL] [Abstract][Full Text] [Related]
4. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
[TBL] [Abstract][Full Text] [Related]
5. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
[TBL] [Abstract][Full Text] [Related]
6. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism.
Reiter E; Mueller C; Pinter B; Krismer F; Scherfler C; Esterhammer R; Kremser C; Schocke M; Wenning GK; Poewe W; Seppi K
Mov Disord; 2015 Jul; 30(8):1068-76. PubMed ID: 25773707
[TBL] [Abstract][Full Text] [Related]
7. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
Taniguchi D; Hatano T; Kamagata K; Okuzumi A; Oji Y; Mori A; Hori M; Aoki S; Hattori N
Mov Disord; 2018 Sep; 33(9):1488-1492. PubMed ID: 29756366
[TBL] [Abstract][Full Text] [Related]
8. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
9. Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
Pyatigorskaya N; Yahia-Cherif L; Gaurav R; Ewenczyk C; Gallea C; Valabregue R; Gargouri F; Magnin B; Degos B; Roze E; Bardinet E; Poupon C; Arnulf I; Vidailhet M; Lehericy S
Mov Disord; 2020 Jan; 35(1):161-170. PubMed ID: 31710146
[TBL] [Abstract][Full Text] [Related]
10. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
Pirker W; Asenbaum S; Bencsits G; Prayer D; Gerschlager W; Deecke L; Brücke T
Mov Disord; 2000 Nov; 15(6):1158-67. PubMed ID: 11104200
[TBL] [Abstract][Full Text] [Related]
11. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH
J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321
[TBL] [Abstract][Full Text] [Related]
12. The Neuropsychology (Broadly Conceived) of Multiple System Atrophy, Progressive Supranuclear Palsy, and Corticobasal Degeneration.
Gerstenecker A
Arch Clin Neuropsychol; 2017 Nov; 32(7):861-875. PubMed ID: 28961692
[TBL] [Abstract][Full Text] [Related]
13. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy.
Lee JH; Han YH; Kang BM; Mun CW; Lee SJ; Baik SK
J Neurol; 2013 Aug; 260(8):2094-101. PubMed ID: 23670309
[TBL] [Abstract][Full Text] [Related]
15. [A 65-year-old man with rigid-bradykinetic parkinsonism, vertical gaze palsy, difficulty of eye-lid opening, and marked pseudo-bulbar palsy].
Noda K; Kobayashi T; Matsuoka S; Takanashi M; Kanazawa A; Mizuno Y
No To Shinkei; 2005 Jan; 57(1):73-86. PubMed ID: 15782604
[TBL] [Abstract][Full Text] [Related]
16. Voxel-based morphometry in autopsy proven PSP and CBD.
Josephs KA; Whitwell JL; Dickson DW; Boeve BF; Knopman DS; Petersen RC; Parisi JE; Jack CR
Neurobiol Aging; 2008 Feb; 29(2):280-9. PubMed ID: 17097770
[TBL] [Abstract][Full Text] [Related]
17. Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Worker A; Blain C; Jarosz J; Chaudhuri KR; Barker GJ; Williams SC; Brown R; Leigh PN; Simmons A
PLoS One; 2014; 9(12):e114167. PubMed ID: 25463618
[TBL] [Abstract][Full Text] [Related]
18. Routine MRI for the differential diagnosis of Parkinson's disease, MSA, PSP, and CBD.
Yekhlef F; Ballan G; Macia F; Delmer O; Sourgen C; Tison F
J Neural Transm (Vienna); 2003 Feb; 110(2):151-69. PubMed ID: 12589575
[TBL] [Abstract][Full Text] [Related]
19. Pathological heterogeneity in progressive supranuclear palsy and corticobasal degeneration.
Wakabayashi K; Takahashi H
Neuropathology; 2004 Mar; 24(1):79-86. PubMed ID: 15068177
[TBL] [Abstract][Full Text] [Related]
20. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI.
Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M
Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
